Skip to main content

Month: August 2025

Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

– WTX-124 Phase 1/1b clinical trial on track for interim data readout in the fourth quarter of 2025, including patients in both the monotherapy and combination expansion arms of cutaneous melanoma and renal cell carcinoma – – Planning to engage with U.S. Food & Drug Administration (FDA) in the second half of 2025 to discuss potential registrational pathways for WTX-124 in advanced or metastatic cutaneous melanoma – – Phase 1b/2 clinical trial of WTX-330 is actively enrolling, with anticipated determination of dosing regimen by the end of 2025 – – Company announces WTX-1011, its first INDUCER™ T-cell engager development candidate, targeting STEAP1 – WATERTOWN, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering...

Continue reading

Prelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

PRT7732, once daily oral SMARCA2 degrader, currently enrolling at the seventh dosing cohort (125 mg); Company to provide an update with preliminary clinical data, including PK/PD, safety and initial clinical activity by year end 2025 Phase 1 study of PRT3789, a once weekly IV SMARCA2 degrader, has been completed; Company to provide final data by year end 2025 Prelude is advancing a development candidate for its oral KAT6A degrader program and remains on track to file an IND in the first half of 2026 Current cash runway into the second quarter of 2026 with $77.3 million in cash, cash equivalents, restricted cash and marketable securities as of June 30, 2025  WILMINGTON, Del., Aug. 14, 2025 (GLOBE NEWSWIRE) — Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported its financial...

Continue reading

BTCS Reports Q2 2025 Results

Record Quarterly Revenue of $2.77 million Post-Quarter ETH Holdings Surpass $321 Million SILVER SPRING, Md., Aug. 14, 2025 (GLOBE NEWSWIRE) — BTCS Inc. (Nasdaq: BTCS) (“BTCS” or the “Company”), a blockchain technology-focused company, short for Blockchain Technology Consensus Solutions, today announced its financial results for the three and six months ended June 30, 2025 (“Q2 2025”). Further, the Company updated its investor presentation, which can be found on its refreshed website at www.btcs.com. “BTCS delivered record quarterly and year-to-date revenues in Q2 2025, surpassing our prior annual revenue record in the first six months of 2025,” said Charles Allen, CEO of BTCS. “Builder+ operations focused on Ethereum drove a 394% year-over-year revenue increase. These achievements are a testament to our successful execution of...

Continue reading

Cellebrite Announces Second-Quarter 2025 Results

Thomas E. Hogan Named CEO ARR grew 21% to $418.9 million; Revenue grew 18% to $113.3 million Net income of $19.5 million supports non-GAAP net income of $30.8 million and adjusted EBITDA of $27.9 million, 24.6% adjusted EBITDA margin TYSONS CORNER, Va. and PETAH TIKVA, Israel, Aug. 14, 2025 (GLOBE NEWSWIRE) — Cellebrite (NASDAQ: CLBT), a global leader in premier Digital Investigative solutions for the public and private sectors, today announced financial results for the three and six months ending June 30, 2025 and the appointment of Thomas E. Hogan as the Company’s CEO. “Cellebrite delivered a strong balance of top-line growth, profitability and cash flow,” stated Thomas E. Hogan, Cellebrite’s CEO. “The Company converted 18% revenue growth into a 29% increase in adjusted EBITDA while free cash flow grew 133% to $29.0 million,...

Continue reading

Unicycive Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update

– Type A Meeting requested with U.S. Food and Drug Administration (FDA) for resolution of the Complete Response Letter (CRL) for oxylanthanum carbonate (OLC) – OLC pivotal study data, published in the Clinical Journal of the American Society of Nephrology (CJASN), demonstrated OLC was well tolerated and enabled serum phosphate control in over 90% of patients with a low pill burden – Ended Q2 with $22.3 million of cash with expected runway into the second half of 2026 LOS ALTOS, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the three months ended June 30, 2025, and provided a business update. “Our team has...

Continue reading

FitLife Brands Announces Second Quarter 2025 Results

OMAHA, NE, Aug. 14, 2025 (GLOBE NEWSWIRE) — FitLife Brands, Inc. (“FitLife” or the “Company”) (NASDAQ: FTLF), a provider of innovative and proprietary nutritional supplements and wellness products, today announced financial results for the second quarter ended June 30, 2025. Highlights for the second quarter ended June 30, 2025 include:Total revenue was $16.1 million, 5% lower than the second quarter of 2024.   Online revenue was $10.4 million, representing 65% of total revenue and down 7% compared to the second quarter of 2024. Gross margin was 42.8% compared to 44.8% during the second quarter of 2024. Net income for the second quarter of 2025 was $1.7 million compared to $2.6 million during the same period last year, with merger and acquisition related expense associated with the Irwin Naturals transaction accounting for most...

Continue reading

atai Life Sciences Reports Second Quarter 2025 Financial Results and Recent Corporate Updates

Planned strategic combination with Beckley Psytech expected to solidify position as global leader in transformative, psychedelic-based mental health therapies with a short time in-clinicReported positive topline data from the core, blinded stage of the Phase 2b clinical trial of BPL-003 (intranasal mebufotenin benzoate) in patients with treatment-resistant depression (TRD) BPL-003 met its primary and all key secondary endpoints, and demonstrated rapid, robust and durable antidepressant effects for up to 8 weeks with a single dose Topline data from the eight-week open-label extension stage of the Phase 2b clinical trial of BPL-003 is expected in the third quarter of 2025 On track to submit End-of-Phase 2 meeting request to the U.S. Food and Drug Administration (FDA) in the third quarter of 2025 Cash, cash equivalents, short-term securities,...

Continue reading

IREN to Release FY25 Results on August 28, 2025

NEW YORK, Aug. 14, 2025 (GLOBE NEWSWIRE) — IREN Limited (NASDAQ: IREN) (“IREN”) today announced that it will release its financial results for the fiscal year ended June 30, 2025, on Thursday, August 28, 2025 and host a conference call beginning at 5:00 p.m. Eastern Time. The webcast will be recorded, and the replay will be accessible shortly after the event at https://iren.com/investor/events-and-presentations Webcast and Conference Call DetailsTime & Date: 5:00 p.m. Eastern Time, Thursday, August 28, 2025    Participant Registration Link    Live Webcast Use this link    Phone Dial-In with Live Q&A Use this link         Participants joining the conference call via the phone dial-in option will receive their dial-in number, passcode and PIN following registration using the link above....

Continue reading

Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Intend to Pursue an NDA Submission to the U.S. FDA under Accelerated Approval Pathway for Iopofosine I 131 for the Treatment of Waldenstrom Macroglobulinemia (WM) Subject to Sufficient Funding and Once the Confirmatory Trial is Underway Continue to Work with the EMA Toward a Potential Submission of Iopofosine I 131 for Conditional Approval in the EU; Decision expected late 3Q early 4Q 2025 On track to advance CLR 125 into Phase 1 TNBC trial 4Q 2025 Company to Hold Webcast and Conference Call at 8:30 AM ET Today FLORHAM PARK, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced financial results for the quarter ended June 30, 2025, and provided a corporate update...

Continue reading

Newton Golf Company Reports Second Quarter 2025 Financial Results

Revenue Climbs 154% Year-over-Year as Tour Adoption and Product Momentum Accelerate CAMARILLO, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) — via IBN – Newton Golf Company (NASDAQ: NWTG) (“Newton Golf” or the “Company”), a technology-forward golf company delivering physics-based performance innovations, today announced financial results for the second quarter ended June 30, 2025. Second Quarter and Year-to-Date 2025 HighlightsQ2 2025: Revenue increased 154% year-over-year to $2.1 million, compared to $813,000 in Q2 2024 First Six Months 2025: Revenue increased 182% year-over-year to $3.3 million, compared to $1.2 million in the first half of 2024 Q2 2025: Gross profit rose 186% to $1.4 million, up from $489,000 in Q2 2024 First Six Months 2025: Gross profit increased 224% to $2.3 million, up from $695,000 in...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.